Epigenetics of bladder cancer: Where biomarkers and therapeutic targets meet
- 1Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Spain
- 2Center for Biomedical Research in Cancer Network (CIBERONC), Spain
- 3Research Institute Hospital October 12, Spain
- 4Centro de Investigación en Medicina Molecular y Enfermedades Crónicas (CiMUS), Spain
- 5Molecular Oncology Unit, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Spain
Bladder cancer (BC) is the most common neoplasia of the urothelial tract. Due to its high incidence, prevalence, recurrence and mortality, it remains an unsolved clinical and social problem. The treatment of BC is challenging and, although immunotherapies have revealed potential benefit in a percentage of patients, it remains mostly as an incurable disease it is advanced state. Epigenetic alterations, including aberrant DNA methylation, altered chromatin remodeling and deregulated expression of non-coding RNAs are common events in BC and can be driver events in BC pathogenesis. Accordingly, these epigenetic alterations are now being used as potential biomarkers for these disorders and are being envisioned as potential therapeutic targets for the future management of BC. In this review, we summarize the recent findings in these emerging and exciting new aspects paving the way for future clinical treatment of this disease.
Keywords: epigenetic, Chromatin remodeling, Bladder cancer, biomarkers, Therapeutic target
Received: 19 Jun 2019;
Accepted: 17 Oct 2019.
Copyright: © 2019 G. Martínez, Munera-Maravilla, Bernardini, Rubio, Suárez-Cabrera, Segovia, Lodewijk, Dueñas, Martínez-Fernández and Paramio. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: PhD. Jesús M. Paramio, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Molecular Oncology Unit, Madrid, 28045, Spain, firstname.lastname@example.org